zolpidem has been researched along with Obesity in 5 studies
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.
zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lorcaserin is a selective and potent serotonin 2C receptor subtype (5-HT(2C)) agonist under development for the treatment of obesity." | 5.15 | Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users. ( Anderson, CM; Bartlett, C; Schoedel, KA; Sellers, EM; Shazer, RL; Shram, MJ, 2011) |
| "Zolpidem (Ambien), a relatively new nonbenzodiazepine sedative-hypnotic, was involved in the death of a 39-year-old obese male who was being treated for depression and insomnia." | 3.69 | Zolpidem tissue concentrations in a multiple drug related death involving Ambien. ( Benson, PA; Macapagal, EC; Meeker, JE; Som, CW, 1995) |
| "16 patients with severe obstructive sleep apnea (apnea+ hypopnea index > 30/hr), on CPAP therapy for at least 6 months." | 2.72 | Effect of zolpidem on the efficacy of continuous positive airway pressure as treatment for obstructive sleep apnea. ( Berry, RB; Patel, PB, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buysse, DJ | 1 |
| Pérez-Díaz, H | 1 |
| Iranzo, A | 1 |
| Santamaría, J | 1 |
| Shram, MJ | 1 |
| Schoedel, KA | 1 |
| Bartlett, C | 1 |
| Shazer, RL | 1 |
| Anderson, CM | 1 |
| Sellers, EM | 1 |
| Berry, RB | 1 |
| Patel, PB | 1 |
| Meeker, JE | 1 |
| Som, CW | 1 |
| Macapagal, EC | 1 |
| Benson, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users[NCT00828659] | Phase 1 | 35 participants (Anticipated) | Interventional | 2008-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for zolpidem and Obesity
| Article | Year |
|---|---|
Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users.
Topics: Adolescent; Adult; Benzazepines; Cross-Over Studies; Double-Blind Method; Female; Humans; Illicit Dr | 2011 |
Effect of zolpidem on the efficacy of continuous positive airway pressure as treatment for obstructive sleep apnea.
Topics: Adult; Arousal; Body Mass Index; Combined Modality Therapy; Continuous Positive Airway Pressure; Cro | 2006 |
3 other studies available for zolpidem and Obesity
| Article | Year |
|---|---|
Toward optimal health: diagnosis and management of disordered sleep in women: Dr. Daniel J Buysse interviewd by Jodi R. Godfrey.
Topics: Behavior Therapy; Cognition Disorders; Comorbidity; Female; Health Status; Humans; Hypnotics and Sed | 2009 |
[Zolpidem-induced sleep-related behavioural disorders].
Topics: Adult; Aged; Animals; Behavior; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Obesity; | 2010 |
Zolpidem tissue concentrations in a multiple drug related death involving Ambien.
Topics: Administration, Oral; Adult; Depression; Drug Overdose; Fatal Outcome; Gas Chromatography-Mass Spect | 1995 |